Everything you care about in one place
Follow feeds: blogs, news, RSS and more. An effortless way to read and digest content of your choice.
Get Feederfiercebiotech.com
FierceBiotech
Get the latest updates from FierceBiotech directly as they happen.
Follow now 340 followers
Latest posts
Last updated about 14 hours ago
Fueled by M&A and partnerships, biotech is poised for continued growth: EY
about 14 hours ago
Biotech’s effervescent activity has allowed it to overcome headwinds and sustain momentum...
Galmed acquires Colospan in $4.5M deal as it eyes $6B GI dx market
about 14 hours ago
Galmed Pharmaceuticals acquired Colospan in a $4.5 million million deal as the...
Cancer biotech Parabilis ups IPO plans to potentially record-setting $637M
about 16 hours ago
Mere months after obesity biotech Kailera Therapeutics netted the biggest initial public...
ADA: AZ’s oral GLP-1 shows ‘competitive efficacy’ in phase 2, setting stage for pivotal program
about 16 hours ago
With a pair of phase 2 readouts, AstraZeneca is positioning itself to...
Lilly moves deeper into Alzheimer’s research with AlzeCure licensing deal
about 16 hours ago
Eli Lilly has signed a heavily backloaded agreement to license a gamma-secretase...
Roche sticks with €600M diagnostics investment in Germany but warns of future risk
about 17 hours ago
As news hit last week that Eli Lilly and Boehringer Ingelheim are...
CeQur nabs $100M series E to fuel insulin patch commercialization
about 17 hours ago
Swiss medtech CeQur has raised $100 million in a series E funding...
The new standard for trusted AI in biopharma
about 18 hours ago
As costs climb, capital tightens and AI enthusiasm accelerates, biopharma leaders are...
With ADA in the books, analyst says Lilly is ‘widening its lead’ in the obesity race
about 18 hours ago
Eli Lilly emerged as the “clear winner from ADA,” according to RBC...
Bial bails after Parkinson’s fail, axing asset over phase 2 miss
about 21 hours ago
Bial has stopped development in a subpopulation of Parkinson’s disease patients after...
GSK inks $10.6B Nuvalent buyout to challenge Roche and Pfizer in lung cancer
about 22 hours ago
GSK has struck a deal to buy Nuvalent for $10.6 billion, securing...
City aims to lay foundation for RNAi renaissance with nearly $100M series B
1 day ago
Looking to spark an antibody-like revolution for RNA interference medicines, City Therapeutics...